Lower urinary tract symptoms such as urinary frequency, urinary urgency, and dysuria are personal feelings of patients with prostate enlargement and are most important to the patients themselves. Due to the different tolerance levels and subjective perceptions of urinary symptoms, lower urinary tract symptoms and the resulting decline in quality of life are the main reasons for patients to seek treatment. Therefore, the degree of lower urinary tract symptoms and quality of life decline is an important basis for the choice of treatment measures. Currently there are four types of treatment for prostate enlargement: wait-and-see, medication, minimally invasive therapy, and surgery. In symptomatic patients, different treatments can be selected based on the patient’s age, symptom score, prostate volume, residual urine, urinary flow rate, serum PSA value, and the presence or absence of complications of prostate enlargement. Symptomatic patients with prostatic hyperplasia do not always need to be treated with medication or surgery because the lower urinary tract symptoms in patients with prostatic hyperplasia occur for complex, multifactorial reasons. Clinically, the condition of patients with prostate hyperplasia is not always gradually aggravated, there are many patients with no change in symptoms for a long time, and no complications of prostate hyperplasia, and some patients’ symptoms will be relieved naturally, and some of them even completely disappeared. After a long period of follow-up, only a small number of patients with prostate enlargement may develop complications such as urinary retention, renal insufficiency and bladder stones. Therefore, wait-and-see can be an appropriate management for most patients with prostatic hyperplasia, especially if the patient’s quality of life has not yet been significantly affected by lower urinary tract symptoms. Wait-and-see is a non-pharmacologic, non-surgical treatment measure that includes patient education, lifestyle guidance, and follow-up visits. Wait-and-see is indicated for patients with mild lower urinary tract symptoms (IPSS score ≤7, or symptoms that have become more than moderate (IPSS score ≥8), but whose quality of life has not yet been significantly affected.